Back to Agenda
Big Data Task Force: So what happens next?
Session Chair(s)
Peter Richard Arlett, MD, FFPM, FRCP
Head Data Analytics and Methods Task Force
European Medicines Agency, Netherlands
The report of the HMA-EMA joint Big Data Task Force was published on 20 January 2020 and made 10 big bold recommendations. So what happens next? Here the recommendations are reviewed and key stakeholders share their views on how we move from recommendations to action for ‘evolving data-driven regulation’.
Speaker(s)
Keynote – 10-priority recommendations from the Big Data Task Force
Nikolai Constantin Brun, MD
Danish Medicines Agency, Denmark
Co-Chair, EMA-MHA Big Data Task Force; Dir, Div for Medical Eval & Biostatistics
Discussant – industry perspective
Nigel Hughes, MSc
Janssen Research and Development, Belgium
Scientific Director, Observational Health Data Analytics/Epidemiology
Discussant – patient perspective
Marco Greco, PhD
European Patients' Forum, Belgium
President
Discussant – policy-makers’ perspective (EC)
Ioana-Maria Gligor
European Commission, Belgium
Head of Unit B3
Academic Priorities and Reflections
Hubert Leufkens, PharmD, PhD
Utrecht University, Netherlands
Emeritus Professor of Pharmaceutical Policy and Regulatory Science
Have an account?